Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors

 Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors

Shots:

  • EirGenix to receive upfront, milestones with profit sharing on sales and will be responsible for the development & manufacturing of proposed biosimilar trastuzumab. Sandoz to get WW rights to commercialize the proposed biosimilar trastuzumab (Ex- China & Taiwan)
  • The agreement is the third biosimilar collaboration for Sandoz in 18 months, which will further focus on the expansion of its oncology portfolio with four oncology biosimilars
  • Proposed trastuzumab biosimilar is been evaluated in P-III study for HER2+ breast and gastric cancer tumors. Additionally, Sandoz has 8 approved biosimilars and 10+ in the development phase for oncology, supportive cancer care, and hematology

Click here to read full press release/ article | Ref: Sandoz | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post